When you receive an Explanation of Benefits (EOB) after a pacemaker procedure, the billing statement can look like an impenetrable wall of medical codes and dollar amounts. But each line item corresponds to a specific device, catheter, medication, laboratory test, or imaging study that was used during your care — and each one carries its own clinical risk profile.
This article uses the billing categories from a combined procedure — extraction of a leadless pacemaker plus implantation of a dual-chamber left bundle branch area pacing (LBBAP) system — to walk through what each component does and what side effects patients should understand.
The Procedure at a Glance
A combined leadless-to-LBBAP upgrade involves two major interventions in a single operating session. First, a previously implanted leadless pacemaker (a self-contained device lodged in the right ventricle) is retrieved through a femoral vein catheter. Second, a new dual-chamber transvenous pacemaker is implanted through axillary vein access, with one lead placed in the right atrium and a specialized thin lead navigated through the interventricular septum to capture the left bundle branch — a technique known as left bundle branch area pacing.
Decoding the Billing Line Items
Below are the procedural components as they appear on a typical insurance claim for this type of case, grouped by clinical function.
Implantable Devices
Pacemaker, dual chamber, rate-responsive (implantable)
Pulse Generator
Lead, pacemaker, other than transvenous VDD single pass
Pacing Leads (×2: atrial + LBB)
Catheters & Access Hardware
Diagnostic electrophysiology catheter, other than 3D mapping
EP Catheter
Catheter, intracardiac echocardiography
ICE Catheter
Guide wire
Vascular Access
Insertable retrieval device, to remove fractured medical devices
Leadless Pacemaker Snare/Retrieval System
Catheter, guiding (may include infusion/perfusion capability)
Guiding Catheter
Fixed-curve intracardiac electrophysiological introducer/sheath
EP Sheath
Non-laser, non-guiding introducer/sheath
Vascular Sheath
Imaging
X-ray of chest, single view
Fluoroscopy / Post-Op Chest X-Ray
Ultrasound evaluation of heart blood vessel
Vascular / Cardiac Ultrasound
Laboratory Tests
Insertion of needle into vein for collection of blood sample
Venipuncture
Screening test for red blood cell antibodies
Antibody Screen
Blood group typing (ABO)
Type & Screen
Blood typing for Rh (D) antigen
Type & Screen
Blood glucose (sugar) test performed by hand-held instrument
Point-of-Care Glucose
Medications
Cefazolin sodium injection
Prophylactic Antibiotic
Injection, heparin sodium
Anticoagulation
Injection, lidocaine hydrochloride
Local Anesthesia
Injection, lidocaine HCl with epinephrine
Local Anesthesia + Vasoconstrictor
Injection, midazolam hydrochloride
Conscious Sedation (Benzodiazepine)
Injection, propofol
Sedation / Anesthesia
Injection, vancomycin hydrochloride
Prophylactic Antibiotic (MRSA Coverage)
Major Procedure Codes
Insertion of new or replacement of permanent pacemaker
LBBAP System Implantation
Removal of permanent leadless pacemaker from lower right heart chamber
Leadless Pacemaker Extraction
Short-Term Side Effects
Acute & Early Post-Procedural Risks
Hours to days to 4 weeks after the procedure
Leadless Pacemaker Extraction: The retrieval catheter and snare system must grasp and dislodge a device that has been encapsulated by cardiac tissue. This carries risk of tricuspid valve injury (the catheter crosses the valve), cardiac perforation leading to tamponade (fluid accumulation around the heart), and femoral vascular complications at the access site. Intracardiac echocardiography (ICE) — one of the billing line items — is used specifically to monitor for perforation in real time.
LBBAP Lead Placement: Navigating the thin-profile lead through the interventricular septum requires precision. Early lead dislodgement is the primary short-term concern, with the highest risk during the first two to four weeks before fibrotic encapsulation stabilizes the lead tip. Septal perforation into the left ventricle is a rare but serious intraoperative complication monitored via fluoroscopy and ICE.
Vascular Access (Axillary Vein): The guide wires and sheaths billed on the claim reflect axillary venous access for the transvenous system. Pneumothorax (collapsed lung) is a recognized risk of upper-extremity venous access, though axillary puncture under ultrasound guidance has a lower incidence than traditional subclavian approaches.
Pocket Hematoma: The subcutaneous pocket created for the pulse generator can accumulate blood, particularly in patients on anticoagulation. The heparin administered during the procedure (visible on the billing) increases this risk.
Infection: Device pocket infection and endocarditis are the most serious infectious complications. The cefazolin and vancomycin on the claim represent the dual-antibiotic prophylaxis strategy recommended by current guidelines. Despite prophylaxis, infection rates for pacemaker implantation range from approximately one to two percent.
Sedation-Related Effects: Midazolam (a benzodiazepine) and propofol (an anesthetic) together provide conscious sedation or monitored anesthesia care. Short-term effects include respiratory depression, transient hypotension, nausea, and post-procedural cognitive fog that typically clears within hours.
Heparin Anticoagulation: Beyond local bleeding risk, heparin carries a small but clinically important risk of heparin-induced thrombocytopenia (HIT) — an immune-mediated platelet drop that can paradoxically cause clotting.
Local Anesthesia (Lidocaine ± Epinephrine): The epinephrine component causes localized vasoconstriction (reducing bleeding) but can produce transient tachycardia. Systemic lidocaine toxicity — perioral numbness, tinnitus, seizures — is rare but possible with inadvertent intravascular injection.
Long-Term Side Effects
Chronic & Late-Onset Considerations
Weeks to months to years after implantation
Capture Threshold Evolution: The LBBAP lead's electrical threshold for capturing the left bundle branch typically rises during the first one to three months as fibrotic tissue encapsulates the lead tip. Most thresholds stabilize, but persistent elevation may require output reprogramming (increasing battery drain) or, rarely, lead revision. Serial interrogation through remote monitoring (e.g., Medtronic CareLink) tracks this closely.
Loss of Selective LBB Capture: The defining advantage of LBBAP is activation of the native conduction system, producing near-normal ventricular synchrony. Over time, septal remodeling or threshold creep can shift capture from selective left bundle branch to non-selective (LBB + local myocardium) or even pure myocardial capture, partially diminishing the synchrony benefit. Regular twelve-lead ECG assessment helps detect this transition.
Lead Integrity Over Years: The thin-profile lead used for LBBAP is subject to the same long-term mechanical stresses as all transvenous leads — conductor fracture, insulation degradation, and connector issues — compounded by its position within the interventricular septum. Lead survival data for LBBAP-specific leads is still maturing compared to conventional pacing leads.
Tricuspid Valve Regurgitation: Any transvenous lead that crosses the tricuspid valve can progressively cause or worsen valve leakage over years through mechanical impingement on the leaflets or chordae. LBBAP leads positioned high in the septum may interact less aggressively with the valve apparatus than traditional right ventricular apical leads, but the risk is not zero and requires echocardiographic surveillance.
Generator Pocket Complications: Over years, the subcutaneous pocket can develop erosion (particularly in thin patients), chronic discomfort, or device migration. In physically active patients — especially those performing repetitive upper-body motions such as rowing, swimming, or overhead lifting — the generator pocket may be subject to additional mechanical stress. Twiddler syndrome (patient manipulation of the device) is rare but documented.
Battery Depletion: The dual-chamber rate-responsive pulse generator has a finite battery life influenced by pacing output voltage, pacing percentage (patients who pace nearly continuously deplete faster), and rate-response sensor activity. Longevity typically ranges from eight to twelve years but varies significantly with programming.
Post-Extraction Endocardial Scarring: The right ventricular site where the leadless pacemaker was extracted may develop endocardial scarring. While generally benign, this tissue could theoretically serve as an arrhythmogenic substrate — a potential origin point for ventricular arrhythmias — though clinical reports of this are exceedingly rare.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. The billing categories described are illustrative and may not represent every patient's specific procedure. Side effect profiles vary based on individual anatomy, operator experience, device selection, and patient comorbidities. Always consult your electrophysiologist or cardiologist for guidance specific to your case.
Frequently Asked Questions
Short-term risks include lead dislodgement (highest in the first two to four weeks), pocket hematoma, pneumothorax from venous access, acute infection, and transient capture threshold instability. Sedation medications used during the procedure can cause respiratory depression, hypotension, and post-procedural cognitive fogginess.
Long-term considerations include capture threshold rise during the first one to three months of lead maturation, potential lead fracture or insulation failure over years, tricuspid valve regurgitation from transvenous leads crossing the valve, generator pocket erosion or discomfort (especially in active patients), battery depletion rates dependent on pacing output, and the theoretical risk of losing selective left bundle branch capture over time.
Leadless pacemaker retrieval carries risks of tricuspid valve damage during catheter passage, cardiac perforation or tamponade, vascular injury at the femoral access site, and device embolization. Intracardiac echocardiography is used during the procedure to monitor for these complications in real time.
A combined leadless extraction and LBBAP implantation involves multiple catheter systems, imaging modalities, laboratory tests, medications, and implantable devices — each billed separately under distinct healthcare billing codes. Understanding these line items helps patients comprehend what happened during their procedure and the clinical rationale behind each component.
These tests (ABO typing, Rh typing, and antibody screening) are standard pre-surgical preparation in case a blood transfusion is needed during or after the procedure. The leadless extraction component carries a small risk of significant bleeding from cardiac perforation, making blood product availability a safety requirement.